IOM’s Lagging Effort for Comments on the $3 Billion California Stem Cell Agency


With the $700,000 Institute of Medicine inquiry into the performance of the California stem cell agency half complete – at least publicly – the blue-ribbon panel seems to be coming up short on comments from outside of the agency itself.

The major public effort by the IOM to secure comments is the passive posting of forms to be filled out on the IOM web site.

How many responses has the IOM received on those forms? The IOM has not disclosed that information despite two inquiries earlier this month by the California Stem Cell Report.

The prestigious institute is undertaking the study of $3 billion agency under contract with CIRM, which is paying the IOM $700,000. Some CIRM directors have expressed hope that the IOM findings will help build support for another multi-billion dollar state bond measure to renew financing for CIRM. It is scheduled to run out of money for new grants in five years.

So far, the IOM panel has held two public meetings, one in Washington, D.C., and one in the San Francisco area. The final California hearing is scheduled for April 10 in Irvine with the last public meetings scheduled for later this year in Washington.

So far, the panel has heard only from CIRM employees or directors as well as researchers who have received tens of millions of dollars in CIRM grants. The IOM has not heard publicly from a single independent witness.

The IOM has posted on its web site forms seeking comments from the public, grant recipients, beneficiary institutions and businesses. However, passive postings of forms are unlikely to generate more than a relative handful of responses. To produce significant numbers requires aggressive and targeted follow-up.

It is also unclear exactly what the IOM is doing to seek information from biotech businesses and unsuccessful grant applicants. Some businesses have complained publicly about the tiny share of funding that industry has received. And some CIRM directors have expressed concern for several years about the inadequacies of business funding.

On Feb. 12, the California Stem Cell Report queried the IOM about its efforts at outreach, asking for specifics on what is being done. Christine Stencel, a spokeswoman for the IOM, replied,

"The IOM has been obtaining and compiling lists of organizations and people to circulate the questionnaires as widely as possible among target groups. For example, IOM has sent a notice to some 300 stakeholder groups encouraging participation."

Other specifics were not forthcoming. (The full text of the questions and responses can be found here.)

On Feb. 15, the California Stem Cell Report followed up with these additional questions,

"Regarding the 300 stakeholder groups, how are those defined? Please give me a few examples.

"Based on your response, is it correct to say that the IOM is not sending out questionnaires directly to all CIRM grant applicants, including those who were rejected?

"Is it correct to say that no special effort -- other than that described in your response -- is being made to seek responses from stem cell businesses?

"The failure to provide numbers on the responses so far would indicate that the numbers are so small that the IOM is choosing not to disclose them. If that is not the case, please email me the numbers."

As of this writing, the IOM has not responded to those questions. We will carry its response verbatim when we receive it.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Text of IOM Statement on Efforts at Soliciting Comment on CIRM


Here is the text of the questions submitted Feb. 12 by the California Stem Cell Report to the Institute of Medicine concerning its attempts to secure comments on the operation of the $3 billion California stem cell agency along with the IOM response.

The response from Christine Stencel, a spokeswoman for the IOM, follows these questions from the California Stem Cell Report.

"I will be writing a piece on Wednesday dealing with the online surveys that IOM has posted. For that piece, please tell me very, very  specifically what the IOM is doing to generate responses. For example, is the IOM buying ads in newspapers or online, asking the public to fill out the forms? Is it hiring a polling firm to call households for responses?  Also please tell me exactly what is being done to generate responses on all the other surveys that have been posted.

"Additionally, please tell me how many responses that the IOM has received so far in each category on the survey forms for CIRM grantees, industry partners and leadership. Thank you."

The IOM response on Feb. 15:

"The IOM has been obtaining and compiling lists of organizations and people to circulate the questionnaires as widely as possible among target groups. For example, IOM has sent a notice to some 300 stakeholder groups encouraging participation. We do not have the resources to hire a polling firm or place ads.

"The purpose of these questionnaires is to extend the committee's information gathering beyond in-person meetings and the standard listing of an email address or phone number for the study on the project website. Not all people who might have useful experiences or perspectives on CIRM may be able to attend the in-person meetings and not all may visit the project website and find the study contact information. This is a proactive effort to reach more people.

"Anyone who knows of individuals or organizations with information on CIRM that would be useful for the committee's knowledge can share the links to the questionnaires with them. This will help spread the word and get the committee insights they need.

"I don't have information on the number of responses so far. Ultimately, as noted at the top of each survey, the responses will be aggregated and de-identified and placed in the public access file in addition to being shared with the committee.

"I trust this will be useful for your readers."

The California Stem Cell Report then asked the following questions on Feb. 15.

"Thank you for your response. A few follow-up questions:
Regarding the 300 stakeholder groups, how are those defined? Please give me a few examples.

"Based on your response, is it correct to say that the IOM is not sending out questionnaires directly to all CIRM grant applicants, including those who were rejected?

"Is it correct to say that no special effort -- other than that described in your response -- is being made to seek responses from stem cell businesses?

"The failure to provide numbers on the responses so far would indicate that the numbers are so small that the IOM is choosing not to disclose them. If that is not the case, please email me the numbers. Thank you."

The IOM had not responded to the follow-up questions as of this writing on Feb. 21.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Dopamine Improves Creativity in Parkinson’s

By Rick Nauert PhD Senior News Editor
Reviewed by John M. Grohol, Psy.D. on February 24, 2012

New research suggests administration of dopamine can uncover latent creative talents among some individuals with Parkinson’s disease.

European scientists discovered Parkinson’s disease patients can suddenly become creative when they take dopamine therapy, producing pictures, sculptures, novels and poetry. However, the extreme focus on the new interests may limit performance of normal daily tasks and social activities.

In the study, Italian researchers studied 36 patients with Parkinson’s disease — 18 with increased artistic production and 18 without — and compared them with 36 healthy controls without Parkinson’s. None of the patients had engaged in artistic hobbies before they took dopamine.

“Patients were included in the artistic group if they started working on creative projects for two or more hours a day after starting taking dopamine” explains lead author Dr Margherita Canesi.

“Our findings suggest that the patients’ newly acquired artistic skills were probably there all along, but did not start to emerge until they took the dopamine therapy.

“They did not appear to be connected with abnormal repetitive behaviors, such as impulse control disorders or punding – stereotyped behavior characterized by an intense fascination with a complex, excessive, non-goal oriented, repetitive activity.

“Other researchers have noted that altered creative drive has been observed in patients who have neurodegenerative diseases or have had a stroke. However the anatomical and physiological understanding of creativity is difficult to establish and quantify.”

Dopamine is a neurotransmitter that helps control the brain’s reward and pleasure centers. It helps to regulate movement and emotional responses and enables people to see rewards and work towards them.
A deficiency in dopamine is the critical factor influencing Parkinson’s disease. Physicians often prescribe dopamine therapy to increase dopamine levels in the brain.

Key findings of the study included:

The artwork presented by the patients was mainly drawings/paintings (83%), poetry/novels (50%) and sculpture (28%). In 78% of cases, the patients showed more than one skill, normally writing plus painting or drawing. Some of the patients produced art that was sold and books that were published, but, at the other end of the scale, some of the creative work was of a very poor quality. By using the Torrence Test of Creative Thinking to compare the three groups, the researchers showed that the artistic Parkinson’s Disease patients had similar overall and individual scores to the healthy controls. However the non-artistic patients had significantly lower overall scores than the healthy controls and significantly lower scores than the artistic patients when it came to the elaboration sub-score. There was no correlation between the Torrence Test of Creative Thinking scores and the scores obtained using the Barratt Impulsivity Scale, one of the oldest and most widely used measures of impulsive personality traits. The researchers also used the Minnesota Impulsive Disorders Interview. This showed that one creative patient was positive for compulsive sexual behaviour, one creative patient for compulsive buying and two creative and three non-creative patients for pathological gambling. However, there was little difference in the Torrence scores for patients who tested positive or negative on the Minnesota scale. None of the patients or healthy controls displayed the stereotyped behaviour measured by the Punding Rating Scale.

“In conclusion, we found that newly acquired creative drive in patients with Parkinson’s Disease, after the introduction of dopaminergic therapy, is not related to impulsivity or impulse control disorders as measured by the Barratt Impulsivity Scale or the Minnesota Impulsive Disorders Interview” says Dr Canesi.

“We believe that their desire to be creative could represent emerging innate skills, possibly linked to repetitive and reward-seeking behaviours. Further studies are needed to support our preliminary observations.”

Source: Wiley-Blackwell

Elderly man holding paint brushes photo by shutterstock.


APA Reference
Nauert PhD, R. (2012). Dopamine Improves Creativity in Parkinson’s. Psych Central. Retrieved on February 25, 2012, from http://psychcentral.com/news/2012/02/24/dopamine-improves-creativity-in-parkinson%e2%80%99s/35229.html

 

See the original post:
Dopamine Improves Creativity in Parkinson’s

Boxing: Freddie Roach on HBO TV Show, Parkinson's Disease, Being Famous – Video

18-01-2012 16:46 Famed boxing coach and trainer to Manny Pacquiao, Amir Khan and others - the inimitable Freddie Roach - talks to SB Nation (www.sbnation.com) in this interview about his new HBO miniseries 'On Freddie Roach'. Roach talks about dealing with his Parkinson's, becoming famous, life at Wild Card Gym, how his relationship with his father pushed him into boxing and much more. For more http://www.twitter.com thelukethomas.tumblr.com

Read more from the original source:
Boxing: Freddie Roach on HBO TV Show, Parkinson's Disease, Being Famous - Video

Boxing: Freddie Roach on HBO TV Show, Parkinson’s Disease, Being Famous – Video

18-01-2012 16:46 Famed boxing coach and trainer to Manny Pacquiao, Amir Khan and others - the inimitable Freddie Roach - talks to SB Nation (www.sbnation.com) in this interview about his new HBO miniseries 'On Freddie Roach'. Roach talks about dealing with his Parkinson's, becoming famous, life at Wild Card Gym, how his relationship with his father pushed him into boxing and much more. For more http://www.twitter.com thelukethomas.tumblr.com

Read more from the original source:
Boxing: Freddie Roach on HBO TV Show, Parkinson's Disease, Being Famous - Video

Parkinson's disease patients get free lifetime access to 23andMe personal genome service.

Share  Email  Print

23andMe are offering free lifetime access to their personal genome service to people who have been diagnosed with Parkinson’s disease for their participation in their Parkinson’s disease research initiative.

Below is a promotional video for the project that highlights Muhammad Ali’s struggle with Parkinson’s disease and his participation in 23andMe’s research program. If you or someone you know has Parkinson’s disease, watch the video, check out the website, and explore your options for participation.

About the Author: Michelle Clement has a B.Sc. in zoology and a M.Sc. in organismal biology, both from The Ohio State University. Her thesis research was on the ecophysiology of epidermal lipids and water homeostasis in house sparrows. She now works as a technical editor for The American Chemical Society. Like this blog on Facebook. Follow on Twitter @physilology.

The views expressed are those of the author and are not necessarily those of Scientific American.

Read the original:
Parkinson's disease patients get free lifetime access to 23andMe personal genome service.

Parkinson’s disease patients get free lifetime access to 23andMe personal genome service.

Share  Email  Print

23andMe are offering free lifetime access to their personal genome service to people who have been diagnosed with Parkinson’s disease for their participation in their Parkinson’s disease research initiative.

Below is a promotional video for the project that highlights Muhammad Ali’s struggle with Parkinson’s disease and his participation in 23andMe’s research program. If you or someone you know has Parkinson’s disease, watch the video, check out the website, and explore your options for participation.

About the Author: Michelle Clement has a B.Sc. in zoology and a M.Sc. in organismal biology, both from The Ohio State University. Her thesis research was on the ecophysiology of epidermal lipids and water homeostasis in house sparrows. She now works as a technical editor for The American Chemical Society. Like this blog on Facebook. Follow on Twitter @physilology.

The views expressed are those of the author and are not necessarily those of Scientific American.

Read the original:
Parkinson's disease patients get free lifetime access to 23andMe personal genome service.

Tai chi may help Parkinson's patients, study concludes

LOS ANGELES — A six-month program of tai chi exercises helped people with various stages of Parkinson's disease improve stability, their ability to walk and reduced the frequency of falls.

A study released this month in the New England Journal of Medicine compared a six-month tailored tai chi program to resistance training and stretching to see which was most effective at improving functional movement, walking and balance for Parkinson's patients.

Researchers randomly assigned 195 men and women ages 40 to 85 who were in stages one to four of Parkinson's disease (on a scale of one to five). Parkinson's is a neurological disorder caused by a loss of neurons that produce dopamine, a chemical involved with muscle function and movement coordination. It can result in tremors, stiffness, poor coordination and more difficulty doing daily activities. It also can lead to a higher risk of falls, which can cause serious injuries.

Tai chi, a discipline that incorporates slow, deliberate movements, plus breathing, has health benefits that include reducing stress and improving balance and posture.

The study participants were randomly assigned to hourlong, twice-weekly sessions of tai chi, resistance training or stretching, for six months. Researchers assessed their status at the beginning of the study, at three and six months, and three months after the study ended.

The tai chi participants did better than the stretching group on a few measures: leaning without losing balance, having better directional control of their body and walking skills. They outperformed the resistance-training group on balance and stride length. Those in the tai chi group also reduced their frequency of falls more than the stretching group, and they were on a par with the resistance group.

Three months after the study ended, those in the tai chi group were able to maintain the benefits they had gained.

"Since many training features in the program are functionally oriented," Oregon Research Institute scientist Fuzhong Li said, "the improvements in the balance and gait measures that we demonstrated highlight the potential of Tai Chi-based movements in rehabilitating patients with these types of problems and, consequently, easing cardinal symptoms of Parkinson's disease and improving mobility, flexibility, balance and range of motion." Li was the lead author of the study.

He added that tai chi has several advantages: "It is a low-cost activity that does not require equipment, it can be done anywhere, at any time, and the movements can be easily learned. It can also be incorporated into a rehabilitation setting as part of existing treatment. Similarly, because of its simplicity, certain aspects of this Tai Chi program can also be prescribed to patients as a self-care/home activity."

Read more here:
Tai chi may help Parkinson's patients, study concludes

Tai chi may help Parkinson’s patients, study concludes

LOS ANGELES — A six-month program of tai chi exercises helped people with various stages of Parkinson's disease improve stability, their ability to walk and reduced the frequency of falls.

A study released this month in the New England Journal of Medicine compared a six-month tailored tai chi program to resistance training and stretching to see which was most effective at improving functional movement, walking and balance for Parkinson's patients.

Researchers randomly assigned 195 men and women ages 40 to 85 who were in stages one to four of Parkinson's disease (on a scale of one to five). Parkinson's is a neurological disorder caused by a loss of neurons that produce dopamine, a chemical involved with muscle function and movement coordination. It can result in tremors, stiffness, poor coordination and more difficulty doing daily activities. It also can lead to a higher risk of falls, which can cause serious injuries.

Tai chi, a discipline that incorporates slow, deliberate movements, plus breathing, has health benefits that include reducing stress and improving balance and posture.

The study participants were randomly assigned to hourlong, twice-weekly sessions of tai chi, resistance training or stretching, for six months. Researchers assessed their status at the beginning of the study, at three and six months, and three months after the study ended.

The tai chi participants did better than the stretching group on a few measures: leaning without losing balance, having better directional control of their body and walking skills. They outperformed the resistance-training group on balance and stride length. Those in the tai chi group also reduced their frequency of falls more than the stretching group, and they were on a par with the resistance group.

Three months after the study ended, those in the tai chi group were able to maintain the benefits they had gained.

"Since many training features in the program are functionally oriented," Oregon Research Institute scientist Fuzhong Li said, "the improvements in the balance and gait measures that we demonstrated highlight the potential of Tai Chi-based movements in rehabilitating patients with these types of problems and, consequently, easing cardinal symptoms of Parkinson's disease and improving mobility, flexibility, balance and range of motion." Li was the lead author of the study.

He added that tai chi has several advantages: "It is a low-cost activity that does not require equipment, it can be done anywhere, at any time, and the movements can be easily learned. It can also be incorporated into a rehabilitation setting as part of existing treatment. Similarly, because of its simplicity, certain aspects of this Tai Chi program can also be prescribed to patients as a self-care/home activity."

Read more here:
Tai chi may help Parkinson's patients, study concludes

Saskatchewan starts to fill trial spots for controversial MS liberation therapy

REGINA - Saskatchewan multiple sclerosis patients hoping to take part in a clinical trial of a controversial treatment may soon get a call from the ministry of health.

But only around 10 per cent of those who applied will actually get that call.

Deb Jordan, a ministry spokeswoman, said 670 people had signed up as of Thursday.

The deadline to apply for the two-year, double-blind trial of liberation therapy was midnight Friday.

Jordan said names will be randomly drawn starting next week to determine who will fill 86 spots in the test taking place in Albany, N.Y.

A successful candidate must be a Saskatchewan resident, under the age of 60 and not had liberation treatment.

"Once we verify that information, then the applicant will be forwarded to the folks who are involved in the clinical trial," said Jordan.

"I want to also emphasize that the fact that a patient may be drawn does not necessarily mean that they will move on to the clinical trial.

"There's the medical assessment that has to take place by the team and it is the ... clinical team that is operating the clinical trial that will ultimately make the decisions about the patients who will be participating in the trial."

Jordan said the process could take several months.

The treatment is based on a hypothesis by Italian vascular surgeon Dr. Paolo Zamboni that a condition he dubbed chronic cerebrospinal venous insufficiency, or CCSVI, may be linked to multiple sclerosis. The theory suggests that narrowed neck veins create a backup of blood that can lead to lesions in the brain and inflammation.

Liberation therapy involves opening up blocked neck veins.

The idea that the condition might be linked to the progressive neurological disease has divided the medical community.

Some patients have reported substantial improvements in their symptoms after the therapy. Other studies have raised doubts about its effectiveness and questioned the benefits when weighed against the risks of complications from the operation.

The procedure is not offered in Canada and some patients have travelled around the world to seek it out.

At least two Canadians have died after having the treatment.

With a population slightly more than one million, Saskatchewan has some of the highest rates of MS in the country. An estimated 3,500 Saskatchewan residents have the illness. Canada's rate of MS is among the highest in the world at 240 per 100,000 people. On the Prairies, the rate is 340 per 100,000 people.

Saskatchewan was the first province to pledge clinical trials when it put up $5 million and issued a call for proposals in October 2010. The goal was to proceed with clinical trials by the spring of 2011.

But last June, the government said only one proposal had been received and it didn't meet criteria set by an expert panel.

That's when the province looked to New York.

The double-blind aspect of the study means only half of the patients will actually receive the treatment. Patients and physicians who do the followup will not know who got the treatment.

Jordan said the number of applications is in an expected range. Not everyone would be interested, she said.

"People have to take the information and assess it and decide for themselves whether they want to participate in a clinical trial or not," she said.

"Very clearly, while 86 Saskatchewan patients will participate in the trial, half will receive the procedure and half will not, so how that may factor into an individual patient's decision making can only be determined by them."

Read more:
Saskatchewan starts to fill trial spots for controversial MS liberation therapy

Mastodon – Aqua Dementia – Video

21-09-2009 19:02 An invitation to clairvoyance It's hard to stand around and watch while they ignore us She is dumped on Used as an ashtray At the expense of an organized association I see the stones in the path we laid It's a question of tomorrow We like to breathe the ancient wind that we have followed A perfect fire to burn the land Before they knew it The sun had fallen Boiling the water where the hydra's crawling The righteous go in blazing fury And we cleanse the earth to bring it down Bring it down And God will watch it burn Releasing souls Within the wrath we wait To be dirt again There is a flame I lit I upon high

View post:
Mastodon - Aqua Dementia - Video

Dead Space 2 Dementia Trailer [HD] – Video

29-04-2010 03:42 Dead Space 2 Dementia Debut Trailer [HD] Developer: EA Redwood Shores Release: 3/31/2011 Genre: Action/Shooter/Horror Platform: PS3/X360/PC Publisher: EA Website: http://www.deadspace.com Follow Machinima on Twitter! Machinima twitter.com Inside Gaming twitter.com Machinima Respawn twitter.com Machinima Entertainment, Technology, Culture twitter.com FOR MORE MACHINIMA, GO TO: http://www.youtube.com FOR MORE GAMEPLAY, GO TO: http://www.youtube.com TAGS: Dead Space 2 Debut Trailer [HD] machinima video game videogame xbox360 xbox 360 microsoft playstation3 ps3 playstation 3 sony computer entertainment scea soe pc steam windows live ea redwood studios new fps first person shooter exclusive 2010 2011 announcement teaser yt:quality=high

Read more:
Dead Space 2 Dementia Trailer [HD] - Video

Money for new dementia schemes

A million pounds is being ploughed into new dementia care schemes in Norfolk and Suffolk, as the two counties work together to tackle one of the biggest health challenges they face.

To send a link to this page to a friend, simply enter their email address below.

The message will include the name and email address you gave us when you signed up.

Email address

  Send link

To send a link to this page to a friend, you must be logged in.

The number of people with dementia is predicted to rise by 51pc in the next 15 years, but in Norfolk the number is

expected to increase by 62pc in that time – pushing the total to above 20,000 – and in Suffolk by 65pc.

Last year the Norfolk and Suffolk Dementia Alliance was launched in a bid to bring together all the health, education social care, private and voluntary organisations working in this area.

The aim of the alliance is to seek out the best research, technology and training to make East Anglia a leader, nationally and internationally, in dementia care.

By working together, the alliance’s partners hope to cut out duplication, improve pathways of care for people with dementia and reduce any postcode lottery that currently exists by rolling out the most successful schemes across the two counties.

The Norfolk and Suffolk Dementia Alliance started out life as a health partnership called the Norfolk and Waveney Health Innovation and Education Cluster (HIEC), which bid for some money from the Department of Health.

It was one of the 17 successful applicants across the country and was awarded £650,000 to use research and innovation, such as assistive technologies, to help the area’s ageing population by improving services.

Now Norfolk and Suffolk county councils have stumped up around £200,000 each, and along with around £350,000 of the HIEC funding the money has now been approved for a series of schemes across the two counties.

These include new dementia cafes, hospital dementia care co-ordinators, a dementia-focused revamp of a hospital ward, reminiscence therapy training, and new physical activity groups for people with dementia.

David Edwards, chairman of the Norfolk and Suffolk Dementia Alliance, said: “This investment makes a major step forward in improving all types of dementia services, both in Norfolk and Suffolk.

“This reflects the powerful alliance of all partners which is so crucial in making significant progress for our population.”

In addition to the £750,000 investment, and funds committed to the ongoing work of creating an integrated ‘whole system’ approach, the Norfolk County Workforce Group, an NHS group aimed at developing the healthcare workforce, is putting in £130,000 of funding for a new postgraduate certificate in dementia leadership at the University of East Anglia over the next two years.

This will enable senior nurses, or health, social or residential care workers at a similar senior level to learn more about how to deliver excellent quality care for people with dementia.

The recent £1m investment is in addition to the £1.2m already invested in dementia related pilot projects such as creating dementia intensive support teams and dementia primary care practitioners funded by the primary care trust.

Willie Cruickshank, of the dementia alliance, said: “Things have got a lot better in the past two or three years in terms of how we recognise dementia but we have a long way to go.

“Times are tight and we need to not just improve what we are doing, but also improve the way we are doing it.

“I firmly believe we need to invest in great crisis prevention.”

Continue reading here:
Money for new dementia schemes

Dementia death risk doubles on some antipsychotics

An analysis of tens of thousands of people in nursing homes in the U.S. suggests that residents who take certain antipsychotic drugs for dementia are at about double the risk of dying compared to residents not taking those specific medications.

All the residents in the study, published Friday in the British Medical Journal (BMJ), were over age 65.

The Harvard Medical School study, the largest ever undertaken among U.S. nursing home residents, focused on 75,445 nursing-home residents from 45 states from 2001 to 2005. Their risks of death were looked at during a six-month period.

The study notes that the U.S. Food and Drug Administration (FDA) warned in 2005 that atypical antipsychotic drugs — also known as second-generation antipsychotics —are associated with an increased risk of death in older people with dementia, but it wasn't know whether the risk depends on the type of drug the person is taking.

In 2008, the FDA expanded that warning to include conventional antipsychotics — also called neuroleptics — a class of drug used to relieve symptoms including hallucinations and delusions, and to calm very aggressive patients.

The Harvard researchers conclude that not all antipsychotic medication carries the same risk of death in older people, and "clinicians may want to consider this evidence when evaluating […] the best approach to treatment of behavioural problems." They also stress the importance of prescribing such drugs in the lowest possible dose, and closely monitoring patients shortly after they start treatment.

As the population ages, dementia — the progressive deterioration in cognitive function, or the ability to process thought — is becoming a very real concern. The Alzheimer Society of Canada, which is lobbying the Canadian government to create a plan to respond to concerns that more than 500,000 people have Alzheimer's or other dementia, with that number expected to double by 2038.

In the U.S., the number of people with some form of dementia is estimated at up to five million.

In the Harvard study, the antipsychotic drugs taken by nursing-home residents included:

Aripiprazole.

Haloperidol.

Olanzapine.

Quetiapine.

Risperidone.

Ziprasidone.

Out of the 75,445 residents, a total of 6,598 died within the six-month study from non-cancer related causes. Patients treated with haloperidol had double the risk of death compared to those taking risperidone, while those taking quetiapine had a reduced risk.

The effect of haloperidol was strongest during the first 40 days of treatment, and that did not change after the dosage was adjusted. Almost half of deaths (49 per cent) were recorded as due to circulatory disorders, 10 per cent due to to brain disorders and 15 due to respiratory disorders.

Besides age, gender and whether a patient had any physical illnesses or lived in a part of the U.S. that may raise their risk of death, the state of the nursing homes they were in — including their size, the occupancy rate, availability of special-care units and staffing levels — were taken into consideration.

The study was partially funded by U.S. National Institute of Mental Health, and researchers reported no funding or relationships with any organizations that may have influenced their work.

More:
Dementia death risk doubles on some antipsychotics

Ataxia Long Term Disability.MOD – Dysarthria speaker gives Long Term Disability Toastmaster speech – Video

14-01-2010 10:05 I have ataxic dysarthria from a stroke in 3/2/08 and had Brain surgery to remove the culprit AVM in 2/26/09. The AVM Cerebellar stroke left me with speech, balance and walking disorders that I have worked hard, through therapy, to over come. I am working with UW PT and the UW speech and hearing clinic. Recovery is a full time job, but if you view other videos of me on UTube, you will see it is paying off. I use Toastmasters to keep me motivated about speaking better. I used to talk for a living so speaking well again is VERY important. The purpose of this speech was to deliver a 8-10 sales presentation that used COMPLEX mulit-sylabic words - like Long-term dis-a-bil-i-ty in-sur-ance. 10 syllables!! Whew! Getting there. (We use these Utube videos to help me practice my speech at the UW and also to track my progress with my threapist/insurance providers etc. UTube rocks! 🙂

Read this article:
Ataxia Long Term Disability.MOD - Dysarthria speaker gives Long Term Disability Toastmaster speech - Video

Exciting developments

The latest research on vitamin E is looking at the lesser-known forms of the vitamin, namely tocotrienols.

IF someone were to run a quick survey as to what is the most common exhortation uttered to a loved one whose health is not optimal, it would probably be, ?Take your vitamins?.

The term ?vitamins? has become part of modern popular nomenclature. It?s a quick and convenient way of assuaging the guilt felt by those who know they are not taking good care of their health.

Of course, nothing beats a healthy diet and lifestyle to take good care of health, but for many who find such activities bothersome and time-consuming, the vitamin appears, rightly or otherwise, to be somewhat of a solution.

The term vitamin describes organic substances that are chemically unrelated, but required in small quantities, for a variety of body functions. These are not manufactured by the body, so they need to be ingested to prevent disorders of metabolism. They can be broadly divided into water-soluble and fat-soluble vitamins.

Most of the vitamins we are familiar with today were ?discovered? in the early part of the 20th century. Through the years, studies have elucidated the many important functions of these substances.

In the next few months, we will be looking at one such vitamin, vitamin E, and the research that has been carried out on the many possible benefits this vitamin can confer.

Vitamin E primer

It is recorded that vitamin E was officially recognised in 1925. In 1969, the US Food and Drug Administration (FDA) formally recognised it as an essential nutrient for humans.

Vitamin E is a fat-soluble compound, and it has many biological functions, of which the best known is its antioxidant function. In a nutshell, it protects cell membranes from oxidation and destruction. Other functions include enzymatic activities, gene expression, and neurological function.

In terms of vitamin E deficiency, it is rare, and overt deficiency symptoms have not been found in healthy people who obtain little vitamin E from their diets.

However, as fat is required to absorb vitamin E, those with fat-malabsorption syndromes (such as Crohn?s Disease) are more likely to become deficient. Deficiency symptoms include peripheral neuropathy, ataxia, skeletal myopathy, retinopathy, and impairment of the immune response.

Those with inherited disorders such as Ataxia and Vitamin E Deficiency (AVED) can have such severe vitamin E deficiency that they develop nerve damage and lose the ability to walk unless they take large doses of supplemental vitamin E.

The first use for vitamin E as a therapeutic agent was conducted in 1938 by Widenbauer. He used wheat germ oil supplement that contains vitamin E on 17 premature newborn infants suffering from growth failure. Eleven out of the original 17 patients recovered and were able to resume normal growth rates.

Since then, many other studies have been carried out on vitamin E that looked at various aspects of health and metabolism.

In general, there are eight isomers of vitamin E, and these can be broadly divided into tocopherols (four sub-types) and tocotrienols (four sub-types).

Tocopherol is an important lipid-soluble antioxidant in the body. It protects cell membranes from oxidation, removing free radical intermediates and preventing oxidation reaction. Tocopherols can be found mostly in wheat germ oil, sunflower, and safflower oils.

Compared to tocopherols, tocotrienols are sparsely studied. This might be due to the fact that they were only discovered after tocopherols. Current research direction is starting to give more prominence to the tocotrienols, the lesser known but more potent antioxidants in the vitamin E family. Palm fruit oil is the richest source of tocotrienols.

Vitamin E and health

Many believe vitamin E has the potential to promote health and prevent diseases. This is because vitamin E is a powerful antioxidant, with additional roles in anti-inflammatory, inhibition of platelet aggregation, and enhancement of the immune system.

Studies, however, have shown mixed results. Several studies have associated higher vitamin E intakes with lower rates of heart diseases while randomised clinical trials raised a doubt on the efficacy of vitamin E supplements to prevent such diseases.

In general, such clinical trials have not provided evidence that intake of vitamin E supplements helps repress cardiovascular disease.

Other studies also looked at the effects of vitamin E on cancer, eye conditions and even cognitive decline. In general, these have not revealed conclusive results.

New directions in vitamin E

Over the years, research on vitamin E has looked mainly at alpha-tocopherol. And while hopes were high that vitamin E supplements would give a positive effect on health, the research does not largely support this notion. The results of the research did not look encouraging: vitamin E, even at large doses, does not decrease mortality in adults and may slightly increase it; it does not improve blood sugar control or decrease the risk of stroke; daily supplementation of vitamin E does not decrease the risk of prostate cancer.

A 2007 study concluded that supplementation with alpha-tocopherol did not reduce the risk of major cardiovascular events in middle aged and older men.

However, recent developments warrant a serious reconsideration of vitamin E. As mentioned, most of the studies above looked at the possible effects of tocopherols, not tocotrienols. Research on tocotrienols has indicated that they have neuroprotective, anti-cancer and cholesterol-lowering properties that are often not exhibited by tocopherols.

The structure of tocotrienols suggests a better penetration into tissues layered with multiple saturated fats, making them more suited for use as supplements and such.

Since the 1980s, there have been more studies on tocotrienol showing that they may be more potent in their antioxidation and other effects than the usual suspects in vitamin E.

There appears to be more to vitamin E than just tocopherols. Research has progressed to a stage where scientists have identified the additional unique properties and benefits of tocotrienols.

Malaysian connection

Looking at the overall research on vitamin E, it is prudent to take the wholesome full spectrum of vitamin E; rather than choosing between tocopherols and tocotrienols, as Mother Nature provides it.

Vitamin E supplements currently available in health food stores consist mainly of d-alpha tocopherol or d-mixed tocopherols.

It is interesting to note that the major form of vitamin E in the Western diet occurs in the form of gamma-tocopherol because of the abundance of soy and corn-derived products. On the other hand, in the Eastern diet, the major form of vitamin E is gamma-tocotrienol from palm fruit oil and rice-derived products. Maybe, the ideal vitamin E formula should consist of all the forms of tocopherols and tocotrienols.

This could explain why Carotech Inc, a public-listed company in Malaysia, is the world?s first and largest producer of natural full spectrum of tocotrienol and tocopherol-complex. It is also the only GMP-certified tocotrienol producer in the world. The company is now working with a number of leading researchers in the world, carrying out studies on tocotrienols and its effects on a wide range of health issues; from liver diseases to prostate cancer, s
kin rejuvenation as well as hair loss.

References:

1. Effects of vitamin E on ruminant animal ? scholarsresearchlibrary.com/ABR-vol2.../ABR-2011-2-4-244-251.

2. US National Institutes of Health ? Dietary Supplement Fact Sheet - Vit E. ods.od.nih.gov/factsheets/vitamine/.

Link:
Exciting developments

In Saguenay, a family takes on a disease that haunts the region

Sonia Gobeil can trace her ancestors to the pioneers who first settled the isolated Saguenay region northeast of Quebec City, but she had never heard of the devastating brain disease they passed on through their genes until her son was diagnosed with it.

The disease, an inherited form of ataxia, affects the part of the brain that co-ordinates movement. It can skip generations and miss entire branches of family trees, only to pop up according to the laws of genetics and chance, leaving most patients in a wheelchair by the time they are 40. It is more common in the Saguenay and Charlevoix regions of Quebec than anywhere else in the world.

More related to this story

The history of the disease there begins with a small population of immigrants from France who first settled the Charlevoix region in the 17th century. Researchers suspect that several of those people carried a copy of a rare genetic mutation that on its own is benign, but can wreak havoc in the brains of those unlucky enough to inherit two copies – one from each parent.

The population grew and, 100 years later, the migrants pushed the government to open the territory around the Saguenay River for settlement. There, they carved out a society in the forested wilderness, largely cut off from the rest of the province and generating their own distinctive genetic map. For generations, families were large – 11 children a household on average in the early 1900s – and marriages outside the Catholic faith were discouraged by the church. The Saguenay also got few newcomers. The first passable road to Quebec City, 200 kilometres away, was opened in 1951.

Today, the Saguenay remains strikingly homogeneous: 98 per cent of its 273,000 residents are francophone Quebeckers, and immigrants make up less than 1 per cent of the population.

The remoteness has produced a form of proud self-reliance, a trait that’s now being put to the service of probing the region’s genetic history and dealing with its legacy. In addition to autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), which Ms. Gobeil’s two sons have, three other genetic diseases are much more common in the region than elsewhere in the world. One causes a buildup of lactic acid in blood and can be deadly; another is an enzyme deficiency that can lead to liver and kidney failure. The third causes a birth defect in which the structure that connects the two hemispheres of the brain is missing or only partially formed. Since 2010, couples have had access to free genetic screening. About 1,800 people have been screened so far for the diseases, which affect one in five in the region. A local group goes into elementary and high schools to teach children about hereditary diseases, using simple devices like beaded necklaces to explain DNA and genetics.

Ms. Gobeil’s first born, François, was three when his pre-school teachers noticed that his gait was awkward when he ran. She and husband Jean Groleau didn’t think the problem was serious. They were shocked when doctors diagnosed the boy, now nine, with ARSACS. Their second son, Laurent, who is now six, also has the disease. François can’t skate or play hockey, which he loves. Both boys have a stiff left leg.

After François was diagnosed, the couple learned there was no treatment and no research under way to find one.

“Knowing there was no research being done was like a punch in the stomach. But at the same time, we saw it as an open door.” The condition is hereditary; we can’t change that they have it. But with research, we can do something about it and try to change the path of the future,” said Ms. Gobeil, a lawyer in Montreal.

Follow this link:
In Saguenay, a family takes on a disease that haunts the region